JP2023505190A - １型糖尿病の治療および予防のための方法および組成物 - Google Patents

１型糖尿病の治療および予防のための方法および組成物 Download PDF

Info

Publication number
JP2023505190A
JP2023505190A JP2022533345A JP2022533345A JP2023505190A JP 2023505190 A JP2023505190 A JP 2023505190A JP 2022533345 A JP2022533345 A JP 2022533345A JP 2022533345 A JP2022533345 A JP 2022533345A JP 2023505190 A JP2023505190 A JP 2023505190A
Authority
JP
Japan
Prior art keywords
amino acid
insulin
acid sequence
chain
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022533345A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023505190A5 (https=
Inventor
メアリー エス． モリス
Original Assignee
ドクター メアリー モリス アンド アソシエイツ リミテッド ライアビリティ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ドクター メアリー モリス アンド アソシエイツ リミテッド ライアビリティ カンパニー filed Critical ドクター メアリー モリス アンド アソシエイツ リミテッド ライアビリティ カンパニー
Publication of JP2023505190A publication Critical patent/JP2023505190A/ja
Publication of JP2023505190A5 publication Critical patent/JP2023505190A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2022533345A 2019-12-06 2020-11-25 １型糖尿病の治療および予防のための方法および組成物 Pending JP2023505190A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962944503P 2019-12-06 2019-12-06
US62/944,503 2019-12-06
PCT/US2020/062159 WO2021113136A1 (en) 2019-12-06 2020-11-25 Methods and compositions for the treatment and prevention of type 1 diabetes

Publications (2)

Publication Number Publication Date
JP2023505190A true JP2023505190A (ja) 2023-02-08
JP2023505190A5 JP2023505190A5 (https=) 2023-11-15

Family

ID=76222225

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022533345A Pending JP2023505190A (ja) 2019-12-06 2020-11-25 １型糖尿病の治療および予防のための方法および組成物

Country Status (12)

Country Link
US (1) US12551537B2 (https=)
EP (2) EP4623900A3 (https=)
JP (1) JP2023505190A (https=)
CN (1) CN115151273A (https=)
AR (1) AR122339A1 (https=)
AU (1) AU2020398147A1 (https=)
CA (1) CA3159054A1 (https=)
DK (1) DK4069278T3 (https=)
FI (1) FI4069278T3 (https=)
PL (1) PL4069278T3 (https=)
TW (1) TW202133876A (https=)
WO (1) WO2021113136A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3159054A1 (en) * 2019-12-06 2021-06-10 Mary S. MORRIS Methods and compositions for the treatment and prevention of type 1 diabetes
CN116847869A (zh) * 2020-10-08 2023-10-03 美商玛丽莫里斯博士联合有限责任公司 用于治疗和预防1型糖尿病的方法和组合物

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006132530A2 (en) * 2005-01-31 2006-12-14 Leiden University Medical Center Methods and means for use in diagnostics and treatment of diabetes
JP2007528902A (ja) * 2004-03-12 2007-10-18 バイオデル， インコーポレイテッド 迅速に作用する薬物送達組成物
JP2015514126A (ja) * 2012-04-16 2015-05-18 アルク−アベッロ エイ／エスＡｌｋ−Ａｂｅｌｌｏ Ａ／Ｓ 非特異的アレルギー免疫療法において使用するための植物プロフィリンポリペプチド
JP2017533239A (ja) * 2014-11-04 2017-11-09 イノファーマックス インコーポレイテッド 不安定または吸収不良薬物の経口投与
WO2018144867A1 (en) * 2017-02-03 2018-08-09 Vanderbilt University Systems, compositions and methods for treating diabetes
WO2018157202A1 (en) * 2017-02-28 2018-09-07 Biolingus Ip Llc Oil based formulations for sublingual and buccal delivery
WO2018234493A1 (en) * 2017-06-23 2018-12-27 Klinikum Rechts Der Isar Der Technischen Universität München A ratio of immune cells as prognostic indicator of therapeutic success in allergen-specific immunotherapy
WO2019050465A1 (en) * 2017-09-08 2019-03-14 Diiamyd Medical Ab STRATIFICATION OF GENOTYPE IN THE TREATMENT AND PREVENTION OF DIABETES

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5487898A (en) 1991-08-26 1996-01-30 Abbott Laboratories Compositions and method for the sublingual or buccal administration therapeutic agents
EP1523993A1 (en) * 1999-12-16 2005-04-20 Eli Lilly & Company Polypeptide compositions with improved stability
CN1409640A (zh) * 1999-12-16 2003-04-09 伊莱利利公司 稳定性改善的多肽组合物
CA2500715A1 (en) * 2002-10-03 2004-04-15 Epimmune Inc. Hla binding peptides and their uses
PL1633876T3 (pl) * 2003-06-17 2009-01-30 Sembiosys Genetics Inc Sposoby wytwarzania insuliny w roślinach
US20070027063A1 (en) 2004-01-12 2007-02-01 Mannkind Corporation Method of preserving the function of insulin-producing cells
EP1725254A4 (en) 2004-02-04 2008-02-13 Univ Columbia ANTI-CD3 IMMUNOTHERAPY AND SPECIFIC ANTIGENS FOR THE TREATMENT OF AUTOIMMUNITY
AU2011202239C1 (en) * 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
WO2012104834A1 (en) * 2011-02-03 2012-08-09 Pharmedica Ltd. New oral dissolving films for insulin administration, for treating diabetes
TW201625668A (zh) * 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US10905727B2 (en) 2016-01-14 2021-02-02 Intrexon Actobiotics N.V. Compositions and methods for the treatment of type 1 diabetes
CA3159054A1 (en) * 2019-12-06 2021-06-10 Mary S. MORRIS Methods and compositions for the treatment and prevention of type 1 diabetes
CN116847869A (zh) 2020-10-08 2023-10-03 美商玛丽莫里斯博士联合有限责任公司 用于治疗和预防1型糖尿病的方法和组合物

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007528902A (ja) * 2004-03-12 2007-10-18 バイオデル， インコーポレイテッド 迅速に作用する薬物送達組成物
WO2006132530A2 (en) * 2005-01-31 2006-12-14 Leiden University Medical Center Methods and means for use in diagnostics and treatment of diabetes
JP2015514126A (ja) * 2012-04-16 2015-05-18 アルク−アベッロ エイ／エスＡｌｋ−Ａｂｅｌｌｏ Ａ／Ｓ 非特異的アレルギー免疫療法において使用するための植物プロフィリンポリペプチド
JP2017533239A (ja) * 2014-11-04 2017-11-09 イノファーマックス インコーポレイテッド 不安定または吸収不良薬物の経口投与
WO2018144867A1 (en) * 2017-02-03 2018-08-09 Vanderbilt University Systems, compositions and methods for treating diabetes
WO2018157202A1 (en) * 2017-02-28 2018-09-07 Biolingus Ip Llc Oil based formulations for sublingual and buccal delivery
WO2018234493A1 (en) * 2017-06-23 2018-12-27 Klinikum Rechts Der Isar Der Technischen Universität München A ratio of immune cells as prognostic indicator of therapeutic success in allergen-specific immunotherapy
WO2019050465A1 (en) * 2017-09-08 2019-03-14 Diiamyd Medical Ab STRATIFICATION OF GENOTYPE IN THE TREATMENT AND PREVENTION OF DIABETES

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BIOMED RESEARCH INTERNATIONAL, vol. 2016, JPN6025015022, 2016, pages 9323804 - 1, ISSN: 0005753465 *
DIABETES CARE, vol. 34, JPN6024044644, 2011, pages 1585 - 1590, ISSN: 0005753466 *
J. EXP. MED., vol. 208(7), JPN6025015021, 2011, pages 1501 - 1510, ISSN: 0005753467 *
感染・炎症・免疫, vol. 41(4), JPN6025015023, 2012, pages 280 - 289, ISSN: 0005753464 *

Also Published As

Publication number Publication date
EP4623900A3 (en) 2025-12-10
US20230018324A1 (en) 2023-01-19
CN115151273A (zh) 2022-10-04
AU2020398147A1 (en) 2022-06-02
CA3159054A1 (en) 2021-06-10
EP4623900A2 (en) 2025-10-01
WO2021113136A1 (en) 2021-06-10
TW202133876A (zh) 2021-09-16
DK4069278T3 (da) 2025-06-30
EP4069278A1 (en) 2022-10-12
AR122339A1 (es) 2022-09-07
US12551537B2 (en) 2026-02-17
PL4069278T3 (pl) 2025-10-06
EP4069278B1 (en) 2025-06-11
EP4069278A4 (en) 2024-01-10
FI4069278T3 (fi) 2025-07-16

Similar Documents

Publication Publication Date Title
EP1928499B1 (en) Use of a dpp-iv inhibitor to reduce hypoglycemic events
Bhavsar et al. Evolution of exenatide as a diabetes therapeutic
EP1988100B1 (en) Derivatives of glucagon-like peptide-2 and their therapeutic use
US7049284B2 (en) Glucagon-like peptide-2 and its therapeutic use
US8481490B2 (en) Method of reducing plasma amylase and/or plasma lipase in patients with pancreatitis
JP6141907B2 (ja) 医薬組成物、治療方法及びその使用
US8962554B2 (en) Oral insulin therapies and protocol
JP2023505190A (ja) １型糖尿病の治療および予防のための方法および組成物
Craig et al. The methionine aminopeptidase 2 inhibitor, TNP-470, enhances the antidiabetic properties of sitagliptin in mice by upregulating xenin
JP2023544832A (ja) １型糖尿病の治療および予防のための方法および組成物
HK40078570A (en) Methods and compositions for the prevention of type 1 diabetes
HK40078570B (en) Methods and compositions for the prevention of type 1 diabetes
Zeitler Considerations regarding the diagnosis and treatment of childhood type 2 diabetes
KR20250019690A (ko) 요법을 위한 gcg/glp1 공동-효능제의 사용 방법
TW202135852A (zh) 用於治療肥胖症之使用升糖素和glp-1共促效劑之組合療法
JP2022522461A (ja) 代謝性障害の処置のための組換えタンパク質の使用
HK1153482A (en) Glucagon-like peptide-2 derivatives and their therapeutic use
HK1149720A (en) Glucagon-like peptide-2 and its therapeutic use

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230803

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250417

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250716

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250916

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250918

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260106

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260409

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260428